Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' SCHMOLL HJ' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 160 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Grothey, A; Schmoll, HJ
      New chemotherapy approaches in colorectal cancer

      CURRENT OPINION IN ONCOLOGY
    2. Rades, D; Kuhnel, G; Wildfang, I; Borner, AR; Schmoll, HJ; Knapp, W
      Localised disease in cancer of unknown primary (CUP): The value of positron emission tomography (PET) for individual therapeutic management

      ANNALS OF ONCOLOGY
    3. Hartmann, JT; Einhorn, L; Nichols, CR; Droz, JP; Horwich, A; Gerl, A; Fossa, SD; Beyer, J; Pont, J; Schmoll, HJ; Kanz, L; Bokemeyer, C
      Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: Results of an international multicenter analysis

      JOURNAL OF CLINICAL ONCOLOGY
    4. Fizazi, K; Tjulandin, S; Salvioni, R; Germa-Lluch, JR; Bouzy, J; Ragan, D; Bokemeyer, C; Gerl, A; Flechon, A; de Bono, JS; Stenning, S; Horwich, A; Pont, J; Albers, P; De Giorgi, U; Bower, M; Bulanov, A; Pizzocaro, G; Aparicio, J; Nichols, CR; Theodore, C; Hartmann, JT; Schmoll, HJ; Kaye, SB; Culine, S; Droz, JP; Mahe, C
      Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy-results from an international study group

      JOURNAL OF CLINICAL ONCOLOGY
    5. Rick, O; Bokemeyer, C; Beyer, J; Hartmann, JT; Schwella, N; Kingreen, D; Neureither, S; Metzner, B; Casper, J; Wandt, H; Hartmann, F; Schmoll, HJ; Derigs, G; Gerl, A; Berdel, WE; Kanz, L; Siegert, W
      Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer

      JOURNAL OF CLINICAL ONCOLOGY
    6. Dempke, W; Schmoll, HJ
      Possible new indications for the treatment with erythropoietin

      MEDIZINISCHE KLINIK
    7. Schmoll, HJ; Krege, S; Souchon, R
      Interdisciplinary concensus on diagnosis and treatment of testicular germ cell tumors: Result of an update - Conference on evidence-based medicine (EBM) (vol 23, pg 603, 2000)

      ONKOLOGIE
    8. Schmoll, HJ
      Oxaliplatin (eloxatin) - Advances in cancer therapy 2001 - Foreword

      ONKOLOGIE
    9. Krege, S; Souchon, R; Schmoll, HJ
      Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: Result of an update conference on evidence-based medicine (EBM)

      EUROPEAN UROLOGY
    10. Dempke, W; Rie, C; Grothey, A; Schmoll, HJ
      Cyclooxygenase-2: a novel target for cancer chemotherapy?

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    11. Fittkau, M; Gerlach, R; Schmoll, HJ
      Protective effect of oral phosphatidylcholine on radiation-induced releaseof intestinal peptidases in rats

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    12. Fittkau, M; Grothey, A; Gerlach, R; Schmoll, HJ
      A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    13. Bokemeyer, C; Droz, JP; Horwich, A; Gerl, A; Fossa, SD; Beyer, J; Pont, J; Schmoll, HJ; Kanz, L; Einhorn, L; Nichols, CR; Hartmann, JT
      Extragonadal seminoma - An international multicenter analysis of prognostic factors and long term treatment outcome

      CANCER
    14. Buchner, T; Hiddemann, W; Schoch, C; Haferlach, T; Eimermacher, H; Staib, P; Balleisen, L; Reis, HE; Pielken, HJ; Reichle, A; Schmoll, HJ; Griesinger, F; Gruneisen, A; Sauerland, MC; Heinecke, A
      Treatment of older patients with acute myeloid leukemia (AML)

      ACUTE LEUKEMIAS VIII: PROGNOSTIC FACTORS AND TREATMENT STRATEGIES
    15. Voigt, W; Bulankin, A; Muller, T; Schoeber, C; Grothey, A; Hoang-Vu, C; Schmoll, HJ
      Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines

      CLINICAL CANCER RESEARCH
    16. Dempke, W; Voigt, W; Grothey, A; Hill, BT; Schmoll, HJ
      Cisplatin resistance and oncogene - a review

      ANTI-CANCER DRUGS
    17. Kollmannsberger, C; Nichols, C; Bamberg, M; Hartmann, JT; Schleucher, N; Beyer, J; Schoffski, P; Derigs, G; Ruther, U; Bohlke, I; Schmoll, HJ; Kanz, L; Bokemeyer, C
      First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases

      ANNALS OF ONCOLOGY
    18. Vanhoefer, U; Rougier, P; Wilke, H; Ducreux, MP; Lacave, AJ; Van Cutsem, E; Planker, M; Dos Santos, JG; Piedbois, P; Paillot, B; Bodenstein, H; Schmoll, HJ; Bleiberg, H; Nordlinger, B; Couvreur, ML; Baron, B; Wils, JA
      Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European organization for research and treatment of cancer gastrointestinal tract cancer cooperative group

      JOURNAL OF CLINICAL ONCOLOGY
    19. von Poblozki, A; Dempke, W; Schmoll, HJ
      Carboxypeptidase-G2 rescue in a patient with MTX-induced renal failure

      MEDIZINISCHE KLINIK
    20. Schmoll, HJ; Krege, S; Souchon, R
      Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: Result of an update-conference on evidence-based medicine (EBM)

      ONKOLOGIE
    21. Schmoll, HJ
      Neoadjuvant and adjuvant treatment concepts in colorectal cancer

      ONKOLOGIE
    22. Schmoll, HJ
      Oxliplatin (Eloxatin) - Advances in cancer therapy - Preface

      ONKOLOGIE
    23. Kellner, O; Voigt, W; Schneyer, U; Dempke, W; Schmoll, HJ
      HCG induced hyperthyreosis in germ cell cancer

      ANTICANCER RESEARCH
    24. Dempke, W; Von Poblozki, A; Grothey, A; Schmoll, HJ
      Human hematopoietic growth factors: Old lessons and new perspectives

      ANTICANCER RESEARCH
    25. Souchon, R; Krege, S; Schmoll, HJ; Albers, P; Beyer, J; Bokemeyer, C; Classen, J; Dieckmann, KP; Hartmann, M; Heidenreich, A; Holtl, W; Kliesch, S; Kohrmann, KU; Kuczyk, M; Schmidberger, H; Weinknecht, S; Winter, E; Wittekind, C; Bamberg, M
      Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors. Results of an update conference based on evidence-based medicine (EBM)

      STRAHLENTHERAPIE UND ONKOLOGIE
    26. Schmoll, HJ
      Active specific immunotherapy for human colon cancer

      STRAHLENTHERAPIE UND ONKOLOGIE
    27. Brieger, P; Marneros, A; Wolf, HH; Schmoll, HJ
      Manic episode in an ifosfamide-treated patient

      GENERAL HOSPITAL PSYCHIATRY
    28. Schmiegel, W; Adler, G; Fruhmorgen, P; Folsch, U; Graeven, U; Layer, P; Petrasch, S; Porschen, R; Pox, C; Sauerbruch, T; Schmoll, HJ; Zeitz, M
      Colorectal cancer: Prevention and early detection in the general population - management in population at risk - endoscopic diagnosis, therapy and follow-up of polyps and cancer

      ZEITSCHRIFT FUR GASTROENTEROLOGIE
    29. Dempke, W; von Poblozki, A; Kellner, O; Wolf, HH; Schmoll, HJ
      Hemorrhagic disorder as initial manifestation of metastatic gastric cancer

      WIENER KLINISCHE WOCHENSCHRIFT
    30. Dempke, W; Voigt, W; Grothey, A; Schmoll, HJ
      Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin

      ANTI-CANCER DRUGS
    31. Bokemeyer, C; Gerl, A; Schoffski, P; Harstrick, A; Niederle, N; Beyer, J; Casper, J; Schmoll, HJ; Kanz, L
      Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer

      JOURNAL OF CLINICAL ONCOLOGY
    32. Dempke, W; Behrmann, C; Schober, C; Buchele, T; Grothey, A; Schmoll, HJ
      Diagnostic and therapeutic management of superior vena cava syndrome

      MEDIZINISCHE KLINIK
    33. Dempke, W; Grothey, A; Schmoll, HJ
      Therapeutic management of pleural and pericardial effusions

      ONKOLOGIE
    34. Grothey, A; Voigt, W; Schober, C; Muller, T; Dempke, W; Schmoll, HJ
      The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    35. Schmoll, HJ; Buchele, T; Grothey, A; Dempke, W
      Where do we stand with 5-fluorouracil?

      SEMINARS IN ONCOLOGY
    36. Bokemeyer, C; Bamberg, M; Albers, J; Schmoll, HJ; Weissbach, L
      UICC Symposium on Testicular Cancer: Guidelines for Standard Care and Future Prospects

      INTERNATIONAL JOURNAL OF CANCER
    37. Bokemeyer, C; Kollmannsberger, C; Harstrick, A; Beyer, J; Gerl, A; Casper, J; Metzner, B; Hartmann, JT; Schmoll, HJ; Kanz, L
      Treatment of patients with cisplatin-refractory testicular germ-cell cancer

      INTERNATIONAL JOURNAL OF CANCER
    38. Fossa, SD; Bokemeyer, C; Gerl, A; Culine, S; Jones, WG; Mead, GM; Germa-Luch, JR; Pont, J; Schmoll, HJ; Tjulandin, S
      Treatment outcome of patients with brain metastases from malignant germ cell tumors

      CANCER
    39. Hartmann, JT; Albrecht, C; Schmoll, HJ; Kuczyk, MA; Kollmannsberger, C; Bokemeyer, C
      Long-term effects on sexual function and fertility after treatment of testicular cancer

      BRITISH JOURNAL OF CANCER
    40. Kellner, O; Dempke, W; Schmoll, HJ
      Glucose infusions - Possible effective treatment option in Ifosfamide-induced encephalopathy

      DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
    41. KORFEL A; SCHEULEN ME; SCHMOLL HJ; GRUNDEL O; HARSTRICK A; KNOCHE M; FELS LM; SKORZEC M; BACH F; BAUMGART J; SASS G; SEEBER S; THIEL E; BERDEL WE
      PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF TITANOCENE DICHLORIDE IN ADULTS WITH ADVANCED SOLID TUMORS

      Clinical cancer research
    42. SCHMOLL HJ
      IS THERE A STANDARD ADJUVANT TREATMENT FOR COLON-CANCER - ARBITER

      European journal of cancer
    43. HARTMANN JT; SCHMOLL E; BOKEMEYER C; FETY R; LUCAS C; GIROUX B; SCHMOLL HJ
      PHASE-I PHARMACOLOGICAL STUDY OF INTRAARTERIALLY INFUSED FOTEMUSTINE FOR COLORECTAL LIVER METASTASES

      European journal of cancer
    44. Schmoll, HJ
      Is there a standard adjuvant treatment for rectal cancer? Arbiter

      EUROPEAN JOURNAL OF CANCER
    45. HARTMANN JT; NICHOLS CR; DROZ JP; HORWICH A; GERL A; FOSSA SD; BEYER J; PONT J; SCHMOLL HJ; BOKEMEYER C
      EXTRAGONADAL GERM-CELL TUMORS (EGGCT) AND HEMATOLOGIC DISORDERS - INCIDENCE AND OUTCOME FROM AN INTERNATIONAL DATABASE

      Annals of oncology
    46. KOHNE CH; SCHOFFSKI P; WILKE H; KAUFER C; ANDREESEN R; OHL U; KLAASEN U; WESTERHAUSEN M; HIDDEMANN W; SCHOTT G; HARSTICK A; BADE J; HORSTER A; SCHUBERT U; HECKER H; DORKEN B; SCHMOLL HJ
      EFFECTIVE BIOMODULATION BY LEUCOVORIN OF HIGH-DOSE INFUSION FLUOROURACIL GIVEN AS A WEEKLY 24-HOUR INFUSION - RESULTS OF A RANDOMIZED TRIALIN PATIENTS WITH ADVANCED COLORECTAL-CANCER

      Journal of clinical oncology
    47. KOLLMANNSBERGER C; BOYER J; DROZ JP; HARSTRICK A; HARTMANN JT; BIRON P; FLECHON A; SCHOFFSKI P; KUCZYK M; SCHMOLL HJ; KANZ L; BOKEMEYER C
      SECONDARY LEUKEMIA FOLLOWING HIGH CUMULATIVE DOSES OF ETOPOSIDE IN PATIENTS TREATED FOR ADVANCED GERM-CELL TUMORS

      Journal of clinical oncology
    48. BOKEMEYER C; HARSTRICK A; BEYER J; METZNER B; RUTHER U; HARTMANN JT; HOLSTEIN K; DERIGS HG; DEWIT R; CASPER J; SCHOFFSKI P; KUHRER I; ILLIGER HJ; KEMPF B; REICHLE A; FOLLER A; HOSSFELD DK; FISCHER JT; BERDEL W; GERHARTZ H; KIRCHNER H; PFLUGER K; OSTERMANN H; KANZ L; SCHMOLL HJ
      FIRST-LINE HIGH-DOSE CHEMOTHERAPY FOR POOR-RISK METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS

      Onkologie
    49. WILS J; SAHMOUD T; SOBRERO A; BLEIBERG H; AHMEDZAI S; BLAZEBY J; BLIJHAM G; CONROY T; CUNNINGHAM D; CURRAN D; DIAZRUBIO E; DUCREUX M; EVANS J; GLIMELIUS B; HUTCHINSON G; KERR D; KIEBERT G; KOHNE H; LABIANCA R; LANGENDIJK R; NITTI D; NORDLINGER B; ROUGIER P; SCHEITHAUER W; SCHMOLL HJ; VANCUTSEM E; WAGENER T; WILKE J; MARINUS A; THERASSE P
      EVALUATION OF CLINICAL EFFICACY OF NEW MEDICAL TREATMENTS IN ADVANCEDCOLORECTAL-CANCER - RESULTS OF A WORKSHOP ORGANIZED BY THE EORTC GITCCG

      Tumori
    50. BEYER J; KRAMAR A; MANDANAS R; LINKESCH W; GREINIX A; DROZ JP; PICO JL; DIEHL A; BOKEMEYER C; SCHMOLL HJ; NICHOLS CR; EINHORN LH; SIEGERT W
      PROGNOSTIC FACTORS FOR HIGH-DOSE CHEMOTHERAPY (HDCT) AS SALVAGE TREATMENT IN GERM-CELL TUMORS (GCT)

      Bone marrow transplantation
    51. DUNN TA; SCHMOLL HJ; RIE C; HARTMANN K; CASPER J
      PRODUCTION AND PRECLINICAL SIGNIFICANCE OF HEMATOPOIETIC PEPTIDE GROWTH-FACTORS (HPGF) IN HUMAN NONSEMINOMATOUS GERM-CELL TUMOR-CELL LINES

      Journal of cancer research and clinical oncology
    52. BOKEMEYER C; HARSTRICK A; BEYER J; METZNER B; RUTHER U; HARTMANN JT; HOLSTEIN K; DERIGS HG; DEWIT R; CASPER J; SCHOFFSKI P; KUHRER I; ILLIGER HJ; KEMPF B; REICHLE A; FOLLER A; HOSSFELD DK; FISCHER JT; BERDEL WE; GERHARTZ HH; KIRCHNER H; PFLUGER KH; OSTERMANN H; KANZ L; SCHMOLL HJ
      THE USE OF DOSE-INTENSIFIED CHEMOTHERAPY IN THE TREATMENT OF METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS

      Seminars in oncology
    53. SCHMOLL HJ; BEYER J
      PROGNOSTIC FACTORS IN METASTATIC GERM-CELL TUMORS

      Seminars in oncology
    54. HARTMANN JT; KOHNE CH; SCHMOLL HJ; DAIKELER T; KANZ L; BOKEMEYER C
      IS CONTINUOUS 24-HOUR INFUSION OF 5-FLUOROURACIL PLUS HIGH-DOSE FOLINIC ACID EFFECTIVE IN PATIENTS WITH PROGRESSIVE OR RECURRENT COLORECTAL-CANCER - A PHASE-II STUDY

      Oncology
    55. FIBICH C; SCHOBER C; SCHMOLL HJ
      TREATMENT OF REFRACTORY AUTOIMMUNE HEMOLYTIC-ANEMIAS WITH MYCOPHENOLATE-MOFFETIL (CELL-SEPT(R))

      British Journal of Haematology
    56. FIBICH C; SCHOBER C; KEGEL T; BULANKIN A; SCHADLICH B; KELLNER O; SCHMOLL HJ
      PACLITAXEL IN COMBINATION CHEMOTHERAPY FOR MOBILIZATION OF PERIPHERAL-BLOOD STEM-CELLS (PBSC) FOR MULTICYCLE HIGH-DOSE CHEMOTHERAPY OF SOLID TUMORS

      British Journal of Haematology
    57. BOKEMEYER C; BERGER CC; HARTMANN JT; KOLLMANNSBERGER C; SCHMOLL HJ; KUCZYK MA; KANZ L
      ANALYSIS OF RISK-FACTORS FOR CISPLATIN-INDUCED OTOTOXICITY IN PATIENTS WITH TESTICULAR CANCER

      British Journal of Cancer
    58. Bokemeyer, C; Harstrick, A; Beyer, J; Metzner, B; Ruther, U; Hartmann, JT; Holstein, K; Derig, HG; De Wit, R; Casper, J; Schoffski, P; Kuhrer, I; Illiger, HJ; Kempf, B; Reichle, A; Foller, A; Hossfeld, DK; Fischer, JT; Berdel, WE; Gerhartz, HH; Kirchner, H; Pfluger, KH; Ostermann, H; Kanz, L; Schmoll, HJ
      The use of intensive chemotherapy for non-seminomatous testicular germ cell tumors

      EUROCANCER 98
    59. HARTMANN JT; SCHMOLL E; BOKEMEYER C; FETY R; LUCAS C; DAGAY L; SCHMOLL HJ
      HEPATIC ARTERIAL INFUSION OF THE NITROSOUREA DERIVATE FOTEMUSTINE FORTHE TREATMENT OF LIVER METASTASES FROM COLORECTAL-CARCINOMA

      Oncology Reports
    60. SCHMOLL HJ
      PROGNOSTIC FACTORS FOR ADVANCED SEMINOMA - A SOLID BASIS FOR CLINICAL-TRIALS

      European journal of cancer
    61. MALEK NP; CASPER J; LOOIJENGA LHJ; STROHMEYER T; SCHMOLL HJ; NORDHEIM A; JANKNECHT R
      QUANTIFICATION OF ADDITIONAL SHORT ARMS OF CHROMOSOME-12 IN GERM-CELLTUMORS USING THE POLYMERASE CHAIN-REACTION

      European journal of cancer
    62. HARTMANN JT; CANDELARIA M; KUCZYK MA; SCHMOLL HJ; BOKEMEYER C
      COMPARISON OF HISTOLOGICAL RESULTS FROM THE RESECTION OF RESIDUAL MASSES AT DIFFERENT SITES AFTER CHEMOTHERAPY FOR METASTATIC NONSEMINOMATOUS GERM-CELL TUMORS

      European journal of cancer
    63. KOHNE CH; HARSTRICK A; HIDDEMANN W; SCHOFFSKI P; WILKE H; BOKEMEYER C; DORKEN B; SCHMOLL HJ
      MODULATION OF 5-FLUOROURACIL WITH METHOTREXATE AND LOW-DOSE N-(PHOSPHONACETYL)-1-ASPARTATE IN PATIENTS WITH ADVANCED COLORECTAL-CANCER - RESULTS OF A PHASE-II STUDY

      European journal of cancer
    64. SCHMOLL HJ; QUIETZSCH D; BORNER P; KETTNER E; MENNIGEN R; ZINGREBE M; PREISS J
      SAFETY OF ADJUVANT MAB 17-1A IN COLORECTAL-CANCER (CRC)

      European journal of cancer
    65. HARTMANN JT; KOHNE CH; SCHMOLL HJ; KOLLMANNSBERGER C; KANZ L; BOKEMEYER C
      PHASE-II STUDY OF 24 HOURS-INFUSION OF 5-FLUOROURACIL AND HIGH-DOSE FOLINIC ACID IN PATIENTS WITH PROGRESSIVE OR RECURRENT COLORECTAL-CANCER (CRC)

      European journal of cancer
    66. BECKER A; BUCHELE T; SANDNER A; WEIGEL C; SCHOBER C; SCHMOLL HJ
      PHASE I-II STUDY OF SIMULTANEOUS RADIOTHERAPY AND PACLITAXEL (TAXOL) IN A TWICE A WEEK (TIW) SCHEDULE FOR RECURRENT SQUAMOUS-CELL CARCINOMAS OF THE HEAD AND NECK (SCCHN)

      European journal of cancer
    67. HARTMANN JT; CANDELARIA M; JACKH G; SCHMOLL HJ; HARSTRICK A; KANZ L; BOKEMEYER C
      CONTINUOUS 120 HOURS-INFUSION OF MITOMYCIN-C (MMC) AS SALVAGE TREATMENT IN PROGRESSIVE OR RAPIDLY RECURRENT GASTRIC-CANCER

      European journal of cancer
    68. HARSTRICK A; KOHNE CH; HIDDEMANN W; PREUSSER P; STRUMBERG D; BERNS T; SEEBER S; WILKE H; SCHMOLL HJ
      MODULATION OF 5-FLUOROURACIL WITH METHOTREXATE AND LOW-DOSE N-(PHOSPHONACETYL)-L-ASPARTATE (PALA) IS INACTIVE IN ADVANCED PANCREATIC-CARCINOMA

      Annals of oncology
    69. HARTMANN JT; SCHMOLL HJ; KUCZYK MA; CANDELARIA M; BOKEMEYER C
      POSTCHEMOTHERAPY RESECTIONS OF RESIDUAL MASSES FROM METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS

      Annals of oncology
    70. BOKEMEYER C; NOWAK P; HAUPT A; METZNER B; KOHNE H; HARTMANN JT; KANZ L; SCHMOLL HJ
      TREATMENT OF BRAIN METASTASES IN PATIENTS WITH TESTICULAR CANCER

      Journal of clinical oncology
    71. HARTMANN JT; SCHMOLL HJ; THIEL I; KANZ L; BOKEMEYER C
      TREATMENT OF PATIENTS WITH MALIGNANT FIBR OUS HISTOCYTOMA OF THE BONEAND REVIEW OF CHEMOTHERAPY RESULTS

      Tumordiagnostik & Therapie
    72. SCHMOLL HJ; BUCHELE T; SCHOBER C
      THE ROLE OF 2ND-LINE CHEMOTHERAPY IN COLORECTAL-CANCER

      Onkologie
    73. SCHMOLL HJ; BAMBERG M; WEISSBACH L
      INTERDISCIPLINARY CONSENSUS CONFERENCE ON DIAGNOSTICS AND THERAPY OF TESTICULAR CARCINOMAS

      Onkologie
    74. WEISSBACH L; BAMBERG M; SCHMOLL HJ
      INTERDISCIPLINARY CONSENSUS CONFERENCE ON DIAGNOSIS AND TREATMENT OF TESTICULAR-TUMORS

      Der Urologe
    75. SELIGER B; DUNN T; SCHWENZER A; CASPER J; HUBER C; SCHMOLL HJ
      ANALYSIS OF THE MHC CLASS-I ANTIGEN PRESENTATION MACHINERY IN HUMAN EMBRYONAL CARCINOMAS - EVIDENCE FOR DEFICIENCIES IN TAP, LMP AND MHC CLASS-I EXPRESSION AND THEIR UP-REGULATION BY IFN-GAMMA

      Scandinavian journal of immunology
    76. VOIGT W; VANHOEFER U; YIN MB; MINDERMAN H; SCHMOLL HJ; RUSTUM YM
      EVALUATION OF TOPOISOMERASE-I CATALYTIC ACTIVITY AS DETERMINANT OF DRUG RESPONSE IN HUMAN CANCER CELL-LINES

      Anticancer research
    77. BERKOVIC D; GRUNDEL O; BERKOVIC K; WILDFANG I; HESS CF; SCHMOLL HJ
      SYNERGISTIC CYTOTOXIC EFFECTS OF ETHER PHOSPHOLIPID ANALOGS AND IONIZING-RADIATION IN HUMAN CARCINOMA-CELLS

      Radiotherapy and oncology
    78. DUNN TA; SCHMOLL HJ; GRUNWALD V; BOKEMEYER C; CASPER J
      COMPARATIVE CYTOTOXICITY OF OXALIPLATIN AND CISPLATIN IN NONSEMINOMATOUS GERM-CELL CANCER CELL-LINES

      Investigational new drugs
    79. KOHNE CH; WILKE H; HIDDEMANN W; BOKEMEYER C; LOHRMANN HP; BODENSTEIN H; PREISS J; RAUSCHECKER H; HILL H; KAUFER C; FISCHER JT; OHL U; URBANITZ D; BALLEISEN L; SCHMOLL HJ
      PHASE-II EVALUATION OF 5-FLUOROURACIL PLUS FOLINIC ACID AND ALPHA-2B-INTERFERON IN METASTATIC COLORECTAL-CANCER

      Oncology
    80. BOKEMEYER C; FRANZKE A; HARTMANN JT; SCHOBER C; ARSENIEV L; METZNER B; LINK H; KANZ L; SCHMOLL HJ
      A PHASE I II STUDY OF SEQUENTIAL, DOSE-ESCALATED, HIGH-DOSE IFOSFAMIDE PLUS DOXORUBICIN WITH PERIPHERAL-BLOOD STEM-CELL SUPPORT FOR THE TREATMENT OF PATIENTS WITH ADVANCED SOFT-TISSUE SARCOMAS/

      Cancer
    81. HARTMANN JT; THIEL I; SCHMOLL HJ; EINSELE H; KANZ L; BOKEMEYER C
      MALIGNANT FIBROUS HISTIOCYTOMA OF BONE - REVIEW OF 13 CASES

      Oncology Reports
    82. SCHMOLL HJ
      DEVELOPMENT OF TREATMENT FOR ADVANCED COLORECTAL-CANCER - INFUSIONAL 5-FU AND THE ROLE OF NEW AGENTS

      European journal of cancer
    83. DUNN TA; SCHMOLL HJ; GRUNWALD V; BOKEMEYER C; CASPER J
      AMIFOSTINE DOES NOT ALTER THE ANTITUMOR-ACTIVITY OF CISPLATIN IN A PRECLINICAL MODEL OF TESTICULAR CANCER

      Anti-cancer drugs
    84. BOKEMEYER C; KUCZYK MA; KOHNE H; EINSELE H; KYNAST B; SCHMOLL HJ
      HEMATOPOIETIC GROWTH-FACTORS AND TREATMENT OF TESTICULAR CANCER - BIOLOGICAL INTERACTIONS, ROUTINE USE AND DOSE-INTENSIVE CHEMOTHERAPY

      Annals of hematology
    85. BOKEMEYER C; KOHRMANN O; TISCHLER J; WEISSBACH L; RATH U; HAUPT A; SCHOFFSKI P; HARSTRICK A; SCHMOLL HJ
      A RANDOMIZED TRIAL OF CISPLATIN, ETOPOSIDE AND BLEOMYCIN (PEB) VERSUSCARBOPLATIN, ETOPOSIDE AND BLEOMYCIN (CEB) FOR PATIENTS WITH GOOD-RISK METASTATIC NONSEMINOMATOUS GERM-CELL TUMORS

      Annals of oncology
    86. BOKEMEYER C; BEYER J; METZNER B; RUTHER U; HARSTRICK A; WEISSBACH L; KOHRMANN U; VERBEEK W; SCHMOLL HJ
      PHASE-II STUDY OF PACLITAXEL IN PATIENTS WITH RELAPSED OR CISPLATIN-REFRACTORY TESTICULAR CANCER

      Annals of oncology
    87. BOKEMEYER C; BERGER CC; KUCZYK MA; SCHMOLL HJ
      EVALUATION OF LONG-TERM TOXICITY AFTER CHEMOTHERAPY FOR TESTICULAR CANCER

      Journal of clinical oncology
    88. BEYER J; KRAMAR A; MANDANAS R; LINKESCH W; GREINIX A; DROZ JP; PICO JL; DIEHL A; BOKEMEYER C; SCHMOLL HJ; NICHOLS CR; EINHORN LH; SIEGERT W
      HIGH-DOSE CHEMOTHERAPY AS SALVAGE TREATMENT IN GERM-CELL TUMORS - A MULTIVARIATE-ANALYSIS OF PROGNOSTIC VARIABLES

      Journal of clinical oncology
    89. SCHUPPERT F; MULLERKUNERT E; STOCKER W; BOKEMEYER C; SCHMOLL HJ; VONZURMUHLEN A; RAMBUSCH EG
      CYTOKINES AND ENDOCRINE SYSTEM - IS IT ME ANINGFUL TO MONITOR MORE THAN THE THYROID-GLAND

      Medizinische Klinik
    90. BOKEMEYER C; KUCZYK MA; KOHNE CH; HAUPT A; SCHMOLL HJ
      THE RISK OF SECONDARY NEOPLASIAS FOLLOWIN G TREATMENT OF MALIGNANT GERM-CELL TUMORS OF THE TESTIS

      Medizinische Klinik
    91. SCHMOLL HJ
      TREATMENT OF GERM-CELL TUMORS - MODEL FOR AN INTERDISCIPLINARY TREATMENT STRATEGY

      Medizinische Klinik
    92. ERLICHMAN C; FINE S; KERR I; HOFFMANN W; GORG C; SCHMOLL HJ; PREUSSER P; THUERLIMANN B; GUSTAVSSON B
      A PHASE-II TRIAL OF 5-FLUOROURACIL AND 1-LEUCOVORIN IN PATIENTS WITH METASTATIC COLORECTAL-CANCER

      American journal of clinical oncology
    93. BOKEMEYER C; KUCZYK MA; DUNN T; SERTH J; HARTMANN K; JONASSON J; PIETSCH T; JONAS U; SCHMOLL HJ
      EXPRESSION OF STEM-CELL FACTOR AND ITS RECEPTOR C-KIT PROTEIN IN NORMAL TESTICULAR TISSUE AND MALIGNANT GERM-CELL TUMORS

      Journal of cancer research and clinical oncology
    94. BOKEMEYER C; KUCZYK MA; SERTH J; HARTMANN JT; SCHMOLL HJ; JONAS U; KANZ L
      TREATMENT OF CLINICAL STAGE-I TESTICULAR CANCER AND A POSSIBLE ROLE FOR NEW BIOLOGICAL PROGNOSTIC PARAMETERS

      Journal of cancer research and clinical oncology
    95. FELS LM; BOKEMEYER C; VANRHEE J; SCHMOLL HJ; STOLTE H
      EVALUATION OF LATE NEPHROTOXICITY IN LONG-TERM SURVIVORS OF HODGKINS-DISEASE

      Oncology
    96. SCHMOLL HJ; CASPER J
      MANAGEMENT OF OTHER NON-CISPLATIN-INDUCED EMESIS

      Oncology
    97. ANDREWS PW; CASPER J; DAMJANOV I; DUGGANKEEN M; GIWERCMAN A; HATA J; VONKEITZ A; LOOIJENGA LHJ; MILLAN JL; OOSTERHUIS JW; PERA M; SAWADA M; SCHMOLL HJ; SKAKKEBAEK NE; VANPUTTEN W; STERN P
      COMPARATIVE-ANALYSIS OF CELL-SURFACE ANTIGENS EXPRESSED BY CELL-LINESDERIVED FROM HUMAN GERM-CELL TUMORS

      International journal of cancer
    98. BOKEMEYER C; FELS LM; DUNN T; VOIGT W; GAEDEKE J; SCHMOLL HJ; STOLTE H; LENTZEN H
      SILIBININ PROTECTS AGAINST CISPLATIN-INDUCED NEPHROTOXICITY WITHOUT COMPROMISING CISPLATIN OR IFOSFAMIDE ANTITUMOR-ACTIVITY

      British Journal of Cancer
    99. BERGER CC; BOKEMEYER C; SCHUPPERT F; SCHMOLL HJ
      ENDOCRINOLOGIC LATE EFFECTS AFTER CHEMOTHERAPY FOR TESTICULAR CANCER

      British Journal of Cancer
    100. GANSER A; HOFMANN WK; HEIL G; OTTMANN OG; FISCHER JT; LANGER W; HERRMANN WK; KNUTH A; HOFFKEN K; KOLBE K; SCHMOLL HJ; HERTENSTEIN B; HOELZER D
      G-CSF-PRIMING COMBINED WITH CHEMOTHERAPY (IDARUBICIN, ARA-C, VP-16) YIELDS HIGH REMISSION RATES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES AND HIGH-RISK AML

      Blood


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/10/20 alle ore 07:43:16